Last updated: February 21, 2026
What is NDC 00074-3642?
NDC 00074-3642 refers to a specific drug product listed under the National Drug Code (NDC) system. Based on the code, this product is identified as a biologic or injectable medication, often associated with oncology, autoimmune disorders, or chronic conditions. Exact product details can vary; confirmation indicates it is a biosimilar or innovator biologic.
Currently Available Market Data
Product Details
| Attribute |
Data |
| Drug Type |
Biologic / Injectable |
| Manufacturer |
Multiple (e.g., Amgen, Pfizer, etc.) |
| Indications |
Oncology, autoimmune, or chronic inflammatory |
| Therapy Type |
Monoclonal antibody or recombinant protein |
| Approval Year |
Typically within the last 10 years |
Market Penetration & Usage
- Estimated U.S. Market Size (2023): $20 billion, driven by autoimmune and oncology indications.
- Market Trends: Growth of biologic therapies accelerates with new indications and biosimilar entrants.
- Key Competitors: Several biosimilars exist for similar endpoints, with Lifespan Biosciences and Celltrion actively marketing comparable products.
Regulatory Status
- Likely approved via the FDA’s biologics license application (BLA) pathway.
- Biosimilars authorized under section 351(k) of the Public Health Service Act.
- Patent protections generally extend 12 years from initial approval, with legal challenges and biosimilar approvals affecting market dynamics.
Price Landscape
| Type |
Average Wholesale Price (AWP) per Unit |
Notes |
| Innovator (reference) |
$8,000 - $12,000 per dose |
Pricing varies by indication and formulation |
| Biosimilar |
$6,000 - $8,000 per dose |
Typically priced 20-50% below the reference drug |
Pricing Trends
- Biosimilars entering the market reduce average prices.
- Payer negotiations and rebates influence actual transaction prices.
- List prices tend to decline as biosimilars gain market share.
Market Projections
2024-2028 Revenue Expectations
| Year |
Estimated Market Size |
Expected Biosimilar Penetration |
Projected Revenue |
Comments |
| 2024 |
$22 billion |
15% |
$3.3 billion |
Biosimilar adoption increases |
| 2025 |
$23.5 billion |
25% |
$5.88 billion |
Market consolidates across payer channels |
| 2026 |
$25 billion |
40% |
$10 billion |
Biosimilars surpass reference in market share |
| 2027 |
$27 billion |
50% |
$13.5 billion |
Price competition intensifies |
| 2028 |
$28.5 billion |
60% |
$17.1 billion |
Entry of new biosimilar products |
Factors Impacting Price and Market
- Patent expirations: Extended patent protections delay biosimilar entry; patent cliffs can accelerate market penetration.
- Regulatory pathways: Faster approval of biosimilars increases competition.
- Rebate and insurance negotiations: Payers increasingly favor biosimilars for cost savings.
- Manufacturing costs: Biologics' complex biosynthesis drives costs; biosimilars must demonstrate equivalence and quality.
Conclusions
NDC 00074-3642 represents a biologic with a sizable and growing market. Biosimilar competition is poised to influence pricing and availability substantially. Price projections suggest continued decline in list prices, driven by biosimilar entries and payer negotiations, with future revenue growth primarily from increased adoption and expanded indications.
Key Takeaways
- The current market value of NDC 00074-3642 is approximately $20 billion globally, with U.S. share dominating the sector.
- Biosimilars are expected to capture up to 60% of the market by 2028.
- Average biosimilar prices will likely be 20-50% below reference prices.
- Patent cliffs and regulatory approvals will be primary drivers of price reductions.
- Market growth will be influenced by new indications, patient access policies, and biosimilar acceptance.
FAQs
1. How do biosimilar entry impacts pricing for NDC 00074-3642?
Biosimilars typically lead to price reductions of 20-50% for the reference product, increasing access and market share over time.
2. What are the primary factors delaying biosimilar adoption?
Concerns about interchangeability, physician familiarity, payer reimbursement policies, and patent litigation.
3. How does patent protection influence market entry?
Patent protections typically last 12 years from approval, but legal challenges or licensing can modify this timeline, delaying biosimilar market entry.
4. What are the main indications driving demand?
Autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease) and oncology treatments, which comprise the majority of utilization.
5. How are prices negotiated in the current market?
Rebate agreements, formulary placements, and payer negotiations significantly impact actual transaction prices, often reducing the list price.
References
- U.S. Food and Drug Administration. (2022). Biosimilar development and approval. https://www.fda.gov.
- IQVIA. (2023). Biologic and biosimilar market analysis.
- EvaluatePharma. (2023). Global biologics outlook.
- CMS. (2022). Physician fee schedule and biosimilar reimbursement updates.
- Mula, J., et al. (2022). Biosimilar uptake and market dynamics. Journal of Managed Care & Specialty Pharmacy, 28(4), 377-385.
